Effects of Daijokito on the pharmacokinetics of H2 blocker ranitidine.

Effects of Daijokito on the pharmacokinetics of H2 blocker ranitidine. - Daijokito effects on pharmacokinetics of ranitidine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013106

Enrollment

Registered

2014-02-14

Start date

2014-02-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteer

Interventions

Daijokito 2.5g ranitidine 300mg

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: healthy volunteer without diseases except for constipation

Exclusion criteria

Exclusion criteria: easily to have loose bowels, smoker

Design outcomes

Primary

Measure	Time frame
pharmacokinetics of ranitidine	—

Countries

Japan

Contacts

Public ContactJunichi Hasegawa

Tottori University Pharmacotherapeutics

hasegawa@med.tottori-u.ac.jp0859-38-6171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026